title: Association of functionally significant Melanocortin-4 but not Melanocortin-3 receptor mutations with severe adult obesity in a large North American case-control study.
abstract: Functionally significant heterozygous mutations in the Melanocortin-4 receptor (MC4R) have been implicated in 2.5% of early onset obesity cases in European cohorts. The role of mutations in this gene in severely obese adults, particularly in smaller North American patient cohorts, has been less convincing. More recently, it has been proposed that mutations in a phylogenetically and physiologically related receptor, the Melanocortin-3 receptor (MC3R), could also be a cause of severe human obesity. The objectives of this study were to determine if mutations impairing the function of MC4R or MC3R were associated with severe obesity in North American adults. We studied MC4R and MC3R mutations detected in a total of 1821 adults (889 severely obese and 932 lean controls) from two cohorts. We systematically and comparatively evaluated the functional consequences of all mutations found in both MC4R and MC3R. The total prevalence of rare MC4R variants in severely obese North American adults was 2.25% (CI(95%): 1.44-3.47) compared with 0.64% (CI(95%): 0.26-1.43) in lean controls (P < 0.005). After classification of functional consequence, the prevalence of MC4R mutations with functional alterations was significantly greater when compared with controls (P < 0.005). In contrast, the prevalence of rare MC3R variants was not significantly increased in severely obese adults [0.67% (CI(95%): 0.27-1.50) versus 0.32% (CI(95%): 0.06-0.99)] (P = 0.332). Our results confirm that mutations in MC4R are a significant cause of severe obesity, extending this finding to North American adults. However, our data suggest that MC3R mutations are not associated with severe obesity in this population.
authors.affiliation: Diabetes Center, University of California San Francisco, San Francisco, CA 94143, USA.
authors.forename: Melissa A
authors.initials: MA
authors.lastname: Calton
authors.forename: Baran A
authors.initials: BA
authors.lastname: Ersoy
authors.forename: Sumei
authors.initials: S
authors.lastname: Zhang
authors.forename: John P
authors.initials: JP
authors.lastname: Kane
authors.forename: Mary J
authors.initials: MJ
authors.lastname: Malloy
authors.forename: Clive R
authors.initials: CR
authors.lastname: Pullinger
authors.forename: Yana
authors.initials: Y
authors.lastname: Bromberg
authors.forename: Len A
authors.initials: LA
authors.lastname: Pennacchio
authors.forename: Robert
authors.initials: R
authors.lastname: Dent
authors.forename: Ruth
authors.initials: R
authors.lastname: McPherson
authors.forename: Nadav
authors.initials: N
authors.lastname: Ahituv
authors.forename: Christian
authors.initials: C
authors.lastname: Vaisse
mesh_terms: D000328:Adult; D016022:Case-Control Studies; D002460:Cell Line; D015331:Cohort Studies; D019295:Computational Biology; D005260:Female; D020022:Genetic Predisposition to Disease; D006801:Humans; D008297:Male; D008875:Middle Aged; D050505:Mutant Proteins / Q000378:metabolism; D009154:Mutation / Q000235:genetics*; D009656:North America; D009767:Obesity, Morbid / Q000235:genetics*; D044104:Receptor, Melanocortin, Type 3 / Q000235:genetics*; D044105:Receptor, Melanocortin, Type 4 / Q000235:genetics*; D013851:Thinness / Q000235:genetics
chemical_list: D050505:Mutant Proteins; D044104:Receptor, Melanocortin, Type 3; D044105:Receptor, Melanocortin, Type 4